Published in J Exp Med on March 01, 1999
Advanced Therapies for Liver Metastases (LiMeT) | NCT04622423
CD4 T cells and their role in antitumor immune responses. J Exp Med (1999) 2.27
Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med (2000) 1.67
Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol (2000) 1.66
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol (2000) 1.52
Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer (2001) 1.44
Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes. J Exp Med (2002) 1.38
Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol (2008) 1.36
Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci U S A (1999) 1.30
Searching for borrelial T cell epitopes associated with antibiotic-refractory Lyme arthritis. Mol Immunol (2008) 1.30
The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein. Proc Natl Acad Sci U S A (2001) 1.27
T-cell epitope vaccine design by immunoinformatics. Open Biol (2013) 1.20
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A (2000) 1.19
The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J (2011) 1.19
Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J Virol (2003) 1.19
Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev (2011) 1.18
Recognition of mycobacterial epitopes by T cells across mammalian species and use of a program that predicts human HLA-DR binding peptides to predict bovine epitopes. Infect Immun (2003) 1.17
CD4 T cells in tumor immunity. Springer Semin Immunopathol (2005) 1.13
Identification of a promiscuous T-cell epitope in Mycobacterium tuberculosis Mce proteins. Infect Immun (2002) 1.08
GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1. J Immunol (2010) 1.05
NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer (2000) 1.01
Processing sites are different in the generation of HLA-A2.1-restricted, T cell reactive tumor antigen epitopes and viral epitopes. Int J Immunopathol Pharmacol (2006) 0.93
An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest (2004) 0.90
Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis. J Exp Med (2002) 0.88
Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein. J Immunother (2004) 0.87
Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol Immunother (2014) 0.86
CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc Natl Acad Sci U S A (2006) 0.86
Most nuclear systemic autoantigens are extremely disordered proteins: implications for the etiology of systemic autoimmunity. Arthritis Res Ther (2005) 0.83
Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res (2016) 0.83
A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes. J Immunother Cancer (2014) 0.81
A Mage3/Heat Shock Protein70 DNA vaccine induces both innate and adaptive immune responses for the antitumor activity. Vaccine (2009) 0.80
The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine. Mol Ther (2011) 0.79
Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling. Adv Immunol (2012) 0.78
Profound tumor-specific Th2 bias in patients with malignant glioma. BMC Cancer (2012) 0.76
Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma. Br J Cancer (2006) 0.75
Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. J Immunother (2016) 0.75
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med (1993) 4.99
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med (1995) 3.67
Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol (1991) 3.58
T cell defined tumor antigens. Curr Opin Immunol (1997) 2.90
Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med (1998) 2.72
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med (1995) 2.02
Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med (1995) 1.99
Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules. Nature (1992) 1.98
Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A (1994) 1.91
Serological identification of human tumor antigens. Curr Opin Immunol (1997) 1.91
High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR. J Immunol (1990) 1.85
Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med (1994) 1.81
Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature (1990) 1.77
Identification and intracellular location of MAGE-3 gene product. Cancer Res (1995) 1.77
Selection of T cell epitopes and vaccine engineering. Methods Enzymol (1991) 1.50
Cytotoxic T cell recognition of an endogenous class I HLA peptide presented by a class II HLA molecule. J Exp Med (1990) 1.46
Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol (1990) 1.39
Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res (1997) 1.38
Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol (1996) 1.34
The role of CD4+ tumor-infiltrating lymphocytes in human solid tumors. Immunol Res (1995) 1.12
HLA class II peptide binding specificity and autoimmunity. Adv Immunol (1997) 1.02
The effect of class II gene transfection on the tumourigenicity of the H-2K-negative mouse leukaemia cell line K36.16. Immunology (1991) 0.97
Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol (1995) 0.97
Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J Immunol (1993) 0.95
CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95). Int J Cancer (1998) 0.95
Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles. Int J Cancer (1994) 0.92
Different modes of peptide interaction enable HLA-DQ and HLA-DR molecules to bind diverse peptide repertoires. J Immunol (1997) 0.89
Use of synthetic peptides to establish anti-human acetylcholine receptor CD4+ cell lines from myasthenia gravis patients. J Immunol (1990) 0.87
Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro. Hum Gene Ther (1998) 0.83
Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells. J Immunol (1997) 0.79
Particulate naturally processed peptides prime a cytotoxic response against human melanoma in vitro. Cancer Res (1996) 0.79
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med (1998) 8.56
Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med (2001) 5.56
Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol (1999) 5.13
CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med (1998) 4.15
Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med (1997) 3.57
Expression of two T cell receptor alpha chains: dual receptor T cells. Science (1993) 3.54
Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell (1993) 3.41
Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol (1991) 3.40
Turnover of carbon isotopes in tail hair and breath CO2 of horses fed an isotopically varied diet. Oecologia (2004) 3.14
Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol (1998) 2.84
Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest (1998) 2.78
Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat Genet (2000) 2.71
The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol (1998) 2.32
Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest (2001) 2.10
The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Invest (2001) 2.05
Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med (1995) 2.02
HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med (1996) 1.99
Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules. Nature (1992) 1.98
Involvement of a cis-element that binds an H2TF-1/NF kappa B like factor(s) in the virus-induced interferon-beta gene expression. Nucleic Acids Res (1989) 1.97
Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol (1997) 1.97
Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer (2010) 1.96
Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest (1997) 1.94
Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol (1999) 1.82
Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med (1994) 1.81
Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J Exp Med (1992) 1.78
Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network. Bioinformatics (1998) 1.77
Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J (1996) 1.74
High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations. Proc Natl Acad Sci U S A (1994) 1.69
Development and validation of the Diabetes Bowel Symptom Questionnaire. Aliment Pharmacol Ther (2003) 1.68
Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med (1995) 1.67
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol (1998) 1.65
Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol Today (1993) 1.64
Quantitative analysis of gene expression in human articular cartilage from normal and osteoarthritic joints. Osteoarthritis Cartilage (2001) 1.63
T-cell clonality in immune responses. Immunol Today (1999) 1.61
Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci (2003) 1.60
Isolation and characterization of Ni-specific T cell clones from patients with Ni-contact dermatitis. J Immunol (1985) 1.59
DNA analysis in juvenile Huntington disease. Eur J Pediatr (1989) 1.58
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
A follow-up report of occupational stress in urban EMT-paramedics. Ann Emerg Med (1989) 1.54
Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Valpha24+ T cells and rapid elimination of effector cells by apoptosis. Eur J Immunol (1998) 1.54
Thymoma associated with systemic lupus erythematosus and immunologic abnormalities. Lupus (2000) 1.53
Selection of T cell epitopes and vaccine engineering. Methods Enzymol (1991) 1.50
Molecular cloning and expression of T11 cDNAs reveal a receptor-like structure on human T lymphocytes. Proc Natl Acad Sci U S A (1987) 1.49
Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life. Am J Gastroenterol (2001) 1.47
Identification of thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy. Thyroid (2001) 1.45
Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: correlation of serum gamma interferon levels with protection. Infect Immun (1992) 1.45
Parents of Children with Asperger Syndrome: What is the Cognitive Phenotype? J Cogn Neurosci (1997) 1.44
dsDNA-, nucleohistone- and DNASE I-reactive T lymphocytes in patients affected by systemic lupus erythematosus: correlation with clinical disease activity. Clin Exp Rheumatol (1997) 1.43
The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood (1998) 1.42
Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol (2001) 1.37
Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation. Am J Respir Crit Care Med (2001) 1.32
Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer (2000) 1.32
A novel linear amphipathic beta-sheet cationic antimicrobial peptide with enhanced selectivity for bacterial lipids. J Biol Chem (2001) 1.30
Secondary structure and location of a magainin analogue in synthetic phospholipid bilayers. Biochemistry (1996) 1.29
Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum. J Immunol (1988) 1.28
Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules. J Immunol (1998) 1.28
Pocket 4 of the HLA-DR(alpha,beta 1*0401) molecule is a major determinant of T cells recognition of peptide. J Exp Med (1995) 1.28
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab (2001) 1.23
Neonatal invariant Valpha24+ NKT lymphocytes are activated memory cells. Eur J Immunol (2000) 1.23
Localization of Th-cell subsets in inflammation: differential thresholds for extravasation of Th1 and Th2 cells. Immunol Today (2000) 1.21
CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br J Cancer (2009) 1.21
Subcellular localization of myosin V in nerve growth cones and outgrowth from dilute-lethal neurons. J Cell Sci (1997) 1.21
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer (2009) 1.20
The circumsporozoite protein gene from NF54, a Plasmodium falciparum isolate used in malaria vaccine trials. Mol Biochem Parasitol (1989) 1.20
Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections. Eur Respir J (2004) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Epitopes recognized by human T cells map within the conserved part of the GP190 of P. falciparum. Science (1988) 1.19
Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol (2000) 1.18
Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford) (2006) 1.17
MAGE-1 gene product is a cytoplasmic protein. Int J Cancer (1994) 1.17
HLA polymorphism and T cell recognition of a conserved region of p190, a malaria vaccine candidate. Int Immunol (1991) 1.16
Identification of disease-specific genes in chronic pancreatitis using DNA array technology. Ann Surg (2001) 1.16
Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. J Immunol (1999) 1.15
Plasmodium falciparum-specific human T cell clones: evidence for helper and cytotoxic activities. Eur J Immunol (1987) 1.14
Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J Immunol (2000) 1.13
Factors associated with prevalent abnormal anal cytology in a large cohort of HIV-infected adults in the United States. J Infect Dis (2010) 1.12
Age-related modifications of the human alphabeta T cell repertoire due to different clonal expansions in the CD4+ and CD8+ subsets. Int Immunol (1998) 1.11
Search for a W' or techni-ρ decaying into WZ in pp Collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2012) 1.10
Residual type 1 immunity in patients genetically deficient for interleukin 12 receptor beta1 (IL-12Rbeta1): evidence for an IL-12Rbeta1-independent pathway of IL-12 responsiveness in human T cells. J Exp Med (2000) 1.09
CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J Immunol (1993) 1.09
A peptide-binding motif for I-A(g7), the class II major histocompatibility complex (MHC) molecule of NOD and Biozzi AB/H mice. J Exp Med (1997) 1.09
Search for new physics with same-sign isolated dilepton events with jets and missing transverse energy. Phys Rev Lett (2012) 1.09
Empirically derived symptom sub-groups correspond poorly with diagnostic criteria for functional dyspepsia and irritable bowel syndrome. A factor and cluster analysis of a patient sample. Aliment Pharmacol Ther (2004) 1.08
Search for supersymmetry at the LHC in events with jets and missing transverse energy. Phys Rev Lett (2011) 1.08
Search for stopped Gluinos in pp collisions at square root s=7 TeV. Phys Rev Lett (2011) 1.07
Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin Endocrinol Diabetes (2000) 1.06
Survey of children supported by long-term mechanical ventilation in Switzerland. Swiss Med Wkly (2001) 1.06
NK cell triggering by the human costimulatory molecules CD80 and CD86. J Immunol (1999) 1.06